MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis-Reference-Cited by-同舟云学术

MUC1 overexpression predicts worse survival in patients with non-small cell lung cancer: evidence from an updated meta-analysis

Published:2017-08-03 Issue:52 Volume:8 Page:90315-90326
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Huang Xing¹,Sun Qi²,Chen Chen³,Zhang Yi¹,Kang Xin⁴,Zhang Jing-Yuan¹,Ma Da-Wei¹,Xia Lei¹,Xu Lin⁵,Xu Xin-Yu¹,Ren Bin-Hui⁵

Affiliation:

1. Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China

2. Department of Cardiothoracic Surgery, Jinling Hospital, Southern Medical University, Nanjing, Jiangsu, China

3. Department of Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China

4. Department of General Surgery, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China

5. Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, Jiangsu, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma;2024-08-13

2. The multifaceted role of MUC1 in tumor therapy resistance;Clinical and Experimental Medicine;2022-12-23

3. Understanding and targeting anoikis in metastasis for cancer therapies;Cell Biology International;2022-12

4. Clinicopathological significance of the overexpression of MUC1 in upper tract urothelial carcinoma and possible application as a diagnostic marker;Pathology International;2022-09-28

5. Phase 1 trial of CV301 in combination with anti‐PD ‐1 therapy in nonsquamous non‐small cell lung cancer;International Journal of Cancer;2022-09-09